CL2007003459A1 - Proceso de preparacion de compuestos derivados de pirimidina; y compuesto intermediario (s)-trans-etil 3-etoxi-7-(4-(4-fluorofenil)-6-isopropil-2-(n-metilmetilsulfonamido)pirimidin-5-il)-5-hidroxihep-2,6-dienoato. - Google Patents

Proceso de preparacion de compuestos derivados de pirimidina; y compuesto intermediario (s)-trans-etil 3-etoxi-7-(4-(4-fluorofenil)-6-isopropil-2-(n-metilmetilsulfonamido)pirimidin-5-il)-5-hidroxihep-2,6-dienoato.

Info

Publication number
CL2007003459A1
CL2007003459A1 CL200703459A CL2007003459A CL2007003459A1 CL 2007003459 A1 CL2007003459 A1 CL 2007003459A1 CL 200703459 A CL200703459 A CL 200703459A CL 2007003459 A CL2007003459 A CL 2007003459A CL 2007003459 A1 CL2007003459 A1 CL 2007003459A1
Authority
CL
Chile
Prior art keywords
methylmethylphonamide
hydroxihep
fluorophenil
isopropil
etoxi
Prior art date
Application number
CL200703459A
Other languages
English (en)
Inventor
Robert Lenger
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003459(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2007003459A1 publication Critical patent/CL2007003459A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CL200703459A 2006-12-01 2007-11-30 Proceso de preparacion de compuestos derivados de pirimidina; y compuesto intermediario (s)-trans-etil 3-etoxi-7-(4-(4-fluorofenil)-6-isopropil-2-(n-metilmetilsulfonamido)pirimidin-5-il)-5-hidroxihep-2,6-dienoato. CL2007003459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86811106P 2006-12-01 2006-12-01

Publications (1)

Publication Number Publication Date
CL2007003459A1 true CL2007003459A1 (es) 2008-08-22

Family

ID=39092852

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703459A CL2007003459A1 (es) 2006-12-01 2007-11-30 Proceso de preparacion de compuestos derivados de pirimidina; y compuesto intermediario (s)-trans-etil 3-etoxi-7-(4-(4-fluorofenil)-6-isopropil-2-(n-metilmetilsulfonamido)pirimidin-5-il)-5-hidroxihep-2,6-dienoato.

Country Status (12)

Country Link
US (1) US20080188657A1 (es)
EP (1) EP2091923A1 (es)
JP (1) JP2010511029A (es)
CN (1) CN101627018A (es)
AR (1) AR064027A1 (es)
AU (1) AU2007327013B2 (es)
CA (1) CA2670456A1 (es)
CL (1) CL2007003459A1 (es)
NZ (1) NZ577218A (es)
TW (1) TW200831469A (es)
WO (1) WO2008065410A1 (es)
ZA (1) ZA200903533B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
ATE349431T1 (de) 2001-07-13 2007-01-15 Astrazeneca Uk Ltd Herstellung von aminopyrimidinverbindungen
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
EP1869005A1 (en) * 2005-04-04 2007-12-26 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
PL2172471T3 (pl) 2007-04-18 2013-08-30 Teva Pharma Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
JP6562213B2 (ja) 2013-08-30 2019-08-21 日産化学株式会社 光学活性５−ヒドロキシ−３−ケトエステル類の製造方法
US9695130B2 (en) 2014-02-06 2017-07-04 Api Corporation Rosuvastatin calcium and process for producing intermediate thereof
CN104356119B (zh) * 2014-10-17 2017-05-03 上海应用技术学院 多取代嘧啶类他汀内酯脱水化合物及其用途
CN104628653B (zh) * 2015-01-28 2018-04-03 湖北益泰药业有限公司 合成瑞舒伐他汀钙关键中间体的方法
CN104744378B (zh) * 2015-02-12 2017-10-13 上海弈柯莱生物医药科技有限公司 一种(e)‑3‑[4‑(4‑氟苯基)‑6‑异丙基‑2‑(n‑甲基‑n‑甲磺酰胺基)嘧啶‑5‑基]丙烯醛的合成方法
CN104744377B (zh) * 2015-02-12 2017-04-26 上海弈柯莱生物医药科技有限公司 一种(e)‑3‑[4‑(4‑氟苯基)‑6‑异丙基‑2‑(n‑甲基‑n‑甲磺酰胺基)嘧啶‑5‑基]丙烯醛的制备方法
CN105153040B (zh) * 2015-10-15 2018-04-13 江苏师范大学 瑞舒伐他汀钙新晶型及其制备方法
CN105461636A (zh) * 2015-12-30 2016-04-06 安徽美诺华药物化学有限公司 一种瑞舒伐他汀甲酯的合成方法
CN105566228B (zh) * 2015-12-30 2019-01-04 安徽美诺华药物化学有限公司 一种瑞舒伐他汀的合成方法
CN111718334B (zh) * 2019-03-20 2022-09-30 鲁南制药集团股份有限公司 一种瑞舒伐他汀钙中间体化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
PL367133A1 (en) * 2001-06-06 2005-02-21 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
ATE349431T1 (de) * 2001-07-13 2007-01-15 Astrazeneca Uk Ltd Herstellung von aminopyrimidinverbindungen
US7064209B2 (en) * 2001-11-14 2006-06-20 Nissan Chemical Industries, Ltd. Process for producing optically active oxoheptenoic acid ester
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
EP1375493A1 (en) * 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004054986A2 (en) * 2002-12-16 2004-07-01 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) * 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CN100351240C (zh) * 2005-01-19 2007-11-28 安徽省庆云医药化工有限公司 瑞舒伐他汀钙的合成方法
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
JP2010511029A (ja) 2010-04-08
CA2670456A1 (en) 2008-06-05
WO2008065410A1 (en) 2008-06-05
AR064027A1 (es) 2009-03-04
US20080188657A1 (en) 2008-08-07
AU2007327013A1 (en) 2008-06-05
CN101627018A (zh) 2010-01-13
ZA200903533B (en) 2010-03-31
TW200831469A (en) 2008-08-01
AU2007327013B2 (en) 2011-01-27
EP2091923A1 (en) 2009-08-26
NZ577218A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
CL2007003459A1 (es) Proceso de preparacion de compuestos derivados de pirimidina; y compuesto intermediario (s)-trans-etil 3-etoxi-7-(4-(4-fluorofenil)-6-isopropil-2-(n-metilmetilsulfonamido)pirimidin-5-il)-5-hidroxihep-2,6-dienoato.
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1813678T3 (da) Fremgangsmåde til fremstilling af glycogen
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
DK2046767T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
CL2007002268A1 (es) Procedimiento de preparacion de compuestos derivados de ciclopropilamina opticamente activo; compuesto intermediario derivado de 2-aril ciclopropancarboxamida opticamente activo.
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
CL2008000069A1 (es) Metodo de preparacion de compuestos derivados de 3,4-dihidroquinolina.
ATE490254T1 (de) Imidazoä1,2-aüpyridin-verbindungen als vegf-r2- hemmer
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
DK1745136T3 (da) Fremgangsmåde til enzymatisk fremstilling af (S)-3-cyano-5-methylhexansyre
DK1968949T3 (da) Forbedret fremgangsmåde til fremstilling af salte af 4-(benzimidazolylmethylamino)-benzamider
EP1861371A4 (en) NEW COMPOUNDS II 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILER ELASTASE
DK2049487T3 (da) Fremgangsmåde til fremstilling af 2-substituerede 5-(1-alkylthio)alkylpyridiner
DK1713801T3 (da) Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
CL2011003009A1 (es) Proceso de preparacion de compuestos derivados de 4-fenil-3,5-(tio)piranodionas; compuesto intermediario; y preparacion de dicho intermediario.
DK1843977T3 (da) Fremgangsmåde til fremstilling af cæsiumhydroxidopløsninger
DK2093217T3 (da) Fremgangsmåde til fremstilling af form X af aripiprazol